scPharmaceuticals (SCPH) Stock Forecast, Price & News

scPharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions

Is scPharmaceuticals a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" scPharmaceuticals stock.
View analyst ratings for scPharmaceuticals or view top-rated stocks.

When is scPharmaceuticals' next earnings date?

scPharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 18th 2022.
View our earnings forecast for scPharmaceuticals.

How were scPharmaceuticals' earnings last quarter?

scPharmaceuticals Inc. (NASDAQ:SCPH) posted its quarterly earnings results on Tuesday, March, 22nd. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.07.
View scPharmaceuticals' earnings history.

What price target have analysts set for SCPH?

2 brokers have issued 1-year price targets for scPharmaceuticals' stock. Their forecasts range from $5.00 to $15.00. On average, they anticipate scPharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 125.2% from the stock's current price.
View analysts' price targets for scPharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are scPharmaceuticals' key executives?

scPharmaceuticals' management team includes the following people:

• Mr. John H. Tucker, Pres, CEO, Principal Exec. Officer, Principal Financial Officer & Director (Age 59, Pay $780.46k) (LinkedIn Profile)
• Ms. Rachael Nokes, Sr. VP of Fin. & Principal Accounting Officer (Age 47, Pay $433.54k)
• Katherine Taudvin, Director of Corp. Devel. & Investor Relations
• Dr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs
• Mr. Michael D. Hassman, Sr. VP of Technical Operations

Who are some of scPharmaceuticals' key competitors?

Some companies that are related to scPharmaceuticals include Imago BioSciences (IMGO), Day One Biopharmaceuticals (DAWN), Adicet Bio (ACET), Praxis Precision Medicines (PRAX), Mawson Infrastructure Group (WIZP), Nkarta (NKTX), Janux Therapeutics (JANX), ANI Pharmaceuticals (ANIP), Y-mAbs Therapeutics (YMAB), Cara Therapeutics (CARA), Arcturus Therapeutics (ARCT), 2seventy bio (TSVT), Tango Therapeutics (TNGX), Basilea Pharmaceutica (BPMUF) and Zealand Pharma A/S (ZEAL).
View all of SCPH's competitors.

What other stocks do shareholders of scPharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX).

When did scPharmaceuticals IPO?

(SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

What is scPharmaceuticals' stock symbol?

scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."

Who are scPharmaceuticals' major shareholders?

scPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include AIGH Capital Management LLC (5.10%), Renaissance Technologies LLC (0.68%), Belvedere Trading LLC (0.59%), Dimensional Fund Advisors LP (0.38%), Simplex Trading LLC (0.08%) and Envestnet Asset Management Inc. (0.04%). Company insiders that own scPharmaceuticals stock include 5Am Partners Iv, Llc, Andrew J Schwab, Jack A Khattar and John H Tucker.
View institutional ownership trends for scPharmaceuticals.

Which institutional investors are selling scPharmaceuticals stock?

SCPH stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Envestnet Asset Management Inc..
View insider buying and selling activity for scPharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying scPharmaceuticals stock?

SCPH stock was bought by a variety of institutional investors in the last quarter, including Belvedere Trading LLC, AIGH Capital Management LLC, Simplex Trading LLC, and Dimensional Fund Advisors LP. Company insiders that have bought scPharmaceuticals stock in the last two years include Andrew J Schwab, Jack A Khattar, and John H Tucker.
View insider buying and selling activity for scPharmaceuticals or or view top insider-buying stocks.

How do I buy shares of scPharmaceuticals?

Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is scPharmaceuticals' stock price today?

One share of SCPH stock can currently be purchased for approximately $4.44.

How much money does scPharmaceuticals make?

scPharmaceuticals has a market capitalization of $121.53 million. The company earns $-28.03 million in net income (profit) each year or ($1.03) on an earnings per share basis.

How many employees does scPharmaceuticals have?

scPharmaceuticals employs 26 workers across the globe.

What is scPharmaceuticals' official website?

The official website for scPharmaceuticals is www.scpharma.com.

How can I contact scPharmaceuticals?

scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at (617) 517-0730 or via email at [email protected].